Mepolizumab Injection (Nucala®) to include use for chronic rhinosinusitis with nasal polyps - 17 Sep 2021
Allergy & Anaphylaxis Australia to made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) on change ot Pharmaceutical Benefits Scheme listing of Mepolizumab Injection (Nucala®) to include use for people diagnosed with chronic rhinosinusitis with nasal polyps.
A&AA Mepolizumab Injection (Nucala) change of PBS listing Sep 2021179.29 KB